Improved risk assessment by integrating molecular and clinicopathological factors in early-stage endometrial cancer-combined analysis of the PORTEC cohorts

Clinical Cancer Research

Volumn 22, Issue 16, 2016, Pages 4215-4224

  Stelloo, Ellen ^a   Nout, Remi A ^a   Osse, Elisabeth M ^a   Jürgenliemk Schulz, Ina J ^b   Jobsen, Jan J ^c   Lutgens, Ludy C ^d   Van Der Steen Banasik, Elzbieta M ^e   Nijman, Hans W ^f   Putter, Hein ^a   Bosse, Tjalling ^a   Creutzberg, Carien L ^a   Smit, Vincent T H B M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c MEDISCH SPECTRUM TWENTE   (Netherlands)

^d MAASTtricht Radiation Oncology Clinic   (Netherlands)

^e Arnhems Radiotherapeutisch Instituut   (Netherlands)

^f UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; ESTROGEN RECEPTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROGESTERONE RECEPTOR; PROTEIN; PROTEIN ARID1A; PROTEIN P53; UNCLASSIFIED DRUG; DNA DIRECTED DNA POLYMERASE ALPHA; POLE PROTEIN, HUMAN; POLY ADP RIBOSE BINDING PROTEIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; CTNNB1 GENE; ENDOMETRIOID ENDOMETRIAL CARCINOMA; ENDOMETRIUM CANCER; FEMALE; GENE; GENE MUTATION; HUMAN; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MICROSATELLITE MARKER; POLE GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK ASSESSMENT; WILD TYPE; AREA UNDER THE CURVE; CANCER GRADING; ENDOMETRIUM TUMOR; GENETICS; MIDDLE AGED; MORTALITY; MUTATION; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR GENE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; AREA UNDER CURVE; BIOMARKERS, TUMOR; DNA POLYMERASE II; ENDOMETRIAL NEOPLASMS; FEMALE; GENES, P53; HUMANS; MIDDLE AGED; MUTATION; NEOPLASM GRADING; NEOPLASM STAGING; POLY-ADP-RIBOSE BINDING PROTEINS; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; RISK ASSESSMENT; SURVIVAL ANALYSIS;

EID: 84982149288     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-2878     Document Type: Article

References (33)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015;65:5-29.
2. Creasman WT, Odicino F, Maisonneuve P, Quinn MA, Beller U, Benedet JL, et al. Carcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006;95 Suppl 1:S105-43.
3. Kong A, Johnson N, Kitchener HC, Lawrie TA. Adjuvant radiotherapy for stage I endometrial cancer: an updated Cochrane systematic review and meta-analysis. J Natl Cancer Inst 2012;104:1625-34.
4. Creutzberg CL, van Putten WL, Koper PC, Lybeert ML, Jobsen JJ, Warlam-Rodenhuis CC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet 2000;355:1404-11.
5. Keys HM, Roberts JA, Brunetto VL, Zaino RJ, Spirtos NM, Bloss JD, et al. A phase III trialof surgery with orwithout adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2004;92:744-51.
6. Colombo N, Preti E, Landoni F, Carinelli S, Colombo A, Marini C, et al. Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;24 Suppl 6:vi33-8.
7. Nout RA, Smit VT, Putter H, Jurgenliemk-Schulz IM, Jobsen JJ, Lutgens LC, et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2) :an open-label, non-inferiority, randomised trial. Lancet 2010;375:816-23.
8. Salvesen HB, Haldorsen IS, Trovik J. Markers for individualised therapy in endometrial carcinoma. Lancet Oncol 2012;13:e353-61.
9. Murali R, Soslow RA, Weigelt B. Classification of endometrial carcinoma: more than two types. Lancet Oncol 2014;15:e268-78.
10. Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013;497:67-73.
11. Stelloo E, Bosse T, Nout RA, MacKay HJ, Church DN, Nijman HW, et al. Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative. Mod Pathol 2015;28:836-44.
12. Talhouk A, McConechy MK, Leung S, Li-Chang HH, Kwon JS, Melnyk N, et al. A clinically applicable molecular-based classification for endometrial cancers. Br J Cancer 2015;113:299-310.
13. Bosse T, Peters EE, Creutzberg CL, Jurgenliemk-Schulz IM, Jobsen JJ, Mens JW, et al. Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer - a pooled analysis of PORTEC 1 and 2 trials. Eur J Cancer 2015;51:1742-50.
14. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 2005;93:387-91.
15. Stelloo E, Nout RA, Naves LC, Ter Haar NT, Creutzberg CL, Smit VT, et al. High concordance of molecular tumor alterations between pre-operative curettage and hysterectomy specimens in patients with endometrial carcinoma. Gynecol Oncol 2014;133:197-204.
16. McConechy MK, Talhouk A, Li-Chang HH, Leung S, Huntsman DG, Gilks CB, et al. Detection of DNA mismatch repair (MMR) deficiencies by immunohistochemistry can effectively diagnose the microsatellite instability (MSI) phenotype in endometrial carcinomas. Gynecol Oncol 2015;137:306-10.
17. Church DN, Stelloo E, Nout RA, Valtcheva N, Depreeuw J, ter HN, et al. Prognostic significance of POLE proofreading mutations in endometrial cancer. J Natl Cancer Inst 2015;107:402.
18. Bosse T, Nout RA, Stelloo E, Dreef E, Nijman HW, Jurgenliemk-Schulz IM, et al. L1 cell adhesion molecule is a strong predictor for distant recurrence and overall survivalin early stage endometrial cancer: pooled PORTEC trial results. Eur J Cancer 2014;50:2602-10.
19. Zeimet AG, Reimer D, Huszar M, Winterhoff B, Puistola U, Azim SA, et al. L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation. J Natl Cancer Inst 2013;105:1142-50.
20. van Gool IC, Eggink FA, Freeman-Mills L, Stelloo E, Marchi E, de BM, et al. POLE proofreading mutations elicit an antitumor immune response in endometrial cancer. Clin Cancer Res 2015;21:3347-55.
21. Howitt BE, Shukla SA, Sholl LM, Ritterhouse LL, Watkins JC, Rodig S, et al. Association of polymerase e-mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1. JAMA Oncol 2015;1:1319-23.
22. Liu Y, Patel L, Mills GB, Lu KH, Sood AK, Ding L, et al. Clinical significance of CTNNB1 mutation and Wnt pathway activation in endometrioid endometrial carcinoma. J Natl Cancer Inst 2014;106.
23. Diaz-Padilla I, Romero N, Amir E, Matias-Guiu X, Vilar E, Muggia F, et al. Mismatch repair status and clinical outcome in endometrial cancer: a systematic review and meta-analysis. Crit Rev Oncol Hematol 2013;88:154-67.
24. Supek F, Lehner B. Differential DNA mismatch repair underlies mutation rate variation across the human genome. Nature 2015;521:81-4.
25. Shinbrot E, Henninger EE, Weinhold N, Covington KR, Goksenin AY, Schultz N, et al. Exonuclease mutations in DNA polymerase epsilon reveal replication strand specific mutation patterns and human origins of replication. Genome Res 2014;24:1740-50.
26. Byron SA, Gartside M, Powell MA, Wellens CL, Gao F, Mutch DG, et al. FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features. PLoS One 2012;7:e30801.
27. Trovik J, Wik E, Werner HM, Krakstad C, Helland H, Vandenput I, et al. Hormone receptor lossin endometrial carcinoma curettage predicts lymph node metastasis and poor outcome in prospective multicentre trial. Eur J Cancer 2013;49:3431-41.
28. Huszar M, Pfeifer M, Schirmer U, Kiefel H, Konecny GE, Ben-Arie A, et al. Up-regulation of L1CAM is linked to loss of hormone receptors and E-cadherin in aggressive subtypes of endometrial carcinomas. J Pathol 2010;220:551-61.
29. Scholten AN, van Putten WL, Beerman H, Smit VT, Koper PC, Lybeert ML, et al. Postoperative radiotherapy for Stage 1 endometrial carcinoma: long-term outcome of the randomized PORTEC trial with central pathology review. Int J Radiat Oncol Biol Phys 2005;63:834-8.
30. Khalifa MA, Dodge J, Covens A, Osborne R, Ackerman I. Slide review in gynecologic oncology ensures completeness of reporting and diagnostic accuracy. Gynecol Oncol 2003;90:425-30.
31. Lax SF, Kurman RJ, Pizer ES, Wu L, Ronnett BM. A binary architectural grading system for uterine endometrial endometrioid carcinoma has superior reproducibility compared with FIGO grading and identifies subsets of advance-stage tumors with favorable and unfavorable prognosis. Am J Surg Pathol 2000;24:1201-8.
32. Conlon N, Leitao MMJr, Abu-Rustum NR, Soslow RA. Grading uterine endometrioid carcinoma: a proposal that binary is best. Am J Surg Pathol 2014;38:1583-7.
33. Alkushi A, Abdul-Rahman ZH, Lim P, Schulzer M, Coldman A, Kalloger SE, et al. Description of a novel system for grading of endometrial carcinoma and comparison with existing grading systems. Am J Surg Pathol 2005;29:295-304.